ALK B ALK-ABELLO A/S

Invitation to the presentation of ALK’s first nine months (Q3) 2025 results on Thursday, 13 November 2025

Invitation to the presentation of ALK’s first nine months (Q3) 2025 results on Thursday, 13 November 2025

ALK (ALKB.DC / OMX: ALK B) will publish its results for the first nine months (Q3) of 2025 in the morning on Thursday, 13 November 2025.

Later on the same day, the company will host a presentation for investors and analysts at 1:30 p.m. CET, where ALK’s management will comment on the results for the first nine months and the outlook and be available for questions.

ALK will be represented by Peter Halling, President & CEO, Claus Steensen Sølje, CFO and Per Plotnikof, VP, Head of IR. 

Live audio webcast

The meeting will be audio webcasted live and be available for replay on .

Conference call

If you wish to participate via telephone, please register for the conference call by using this link: and follow the instructions. You will receive an email from with dial-in details, including a passcode and a pin code. Please make sure to whitelist  and/or check your spam filter. We advise you to register on the day before the call at the latest.

Presentation

The presentation will be available on shortly before the meeting starts.

ALK-Abelló A/S

For further information please contact:

Investor Relations: Per Plotnikof, tel. , mobile

Media: Maiken Riise Andersen, tel.

About ALK

ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,800 people worldwide and is listed on Nasdaq Copenhagen. Find more information at

Attachment



EN
06/11/2025

Underlying

ALK BALK-ABELLO A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALK-ABELLO A/S

 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Invitation til præsentation af ALK’s regnskab for de første ni måneder...

Invitation til præsentation af ALK’s regnskab for de første ni måneder (Q3) 2025 torsdag den 13. november 2025 ALK (ALKB.DC / OMX: ALK B) offentliggør delårsrapport for de første ni måneder (Q3) af 2025 om morgenen torsdag den 13. november 2025. ALK afholder senere samme dag kl. 13.30 en præsentation for investorer og analytikere, hvor ledelsen kommenterer på resultat og forventninger samt besvarer spørgsmål. ALK vil være repræsenteret ved Peter Halling, Adm. direktør, Claus Steensen Sølje, Finansdirektør og Per Plotnikof, IR-chef.  Live audio-webcast Mødet audiocastes live på , hvor g...

18h / 22m 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Invitation to the presentation of ALK’s first nine months (Q3) 2025 re...

Invitation to the presentation of ALK’s first nine months (Q3) 2025 results on Thursday, 13 November 2025 ALK (ALKB.DC / OMX: ALK B) will publish its results for the first nine months (Q3) of 2025 in the morning on Thursday, 13 November 2025. Later on the same day, the company will host a presentation for investors and analysts at 1:30 p.m. CET, where ALK’s management will comment on the results for the first nine months and the outlook and be available for questions. ALK will be represented by Peter Halling, President & CEO, Claus Steensen Sølje, CFO and Per Plotnikof, VP, Head of IR.  ...

18h / 22m 1 EN
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
11/02/25 November 2, 2025 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

ALK og GenSci indgår partnerskab om at udvide AIT-markedet i Kina

ALK og GenSci indgår partnerskab om at udvide AIT-markedet i Kina Intern viden GenSci tildeles eksklusive rettigheder til ALK’s AIT-produkter mod husstøvmideallergi i Kina.ALK vil være berettiget til upfront- og milepælsbetalinger på op til DKK 1,3 milliarder ud over indtægter fra levering af produkter til GenSci.Partnerskabet har også til formål at fremskynde introduktionen af en bredere portefølje i Kina.Partnerskabet forventes at understøtte indtjeningsmarginen på mellemlangt sigt, men forventes ikke at have væsentlig indvirkning på ALK’s omsætning og indtjening (EBIT) i 2025. ALK (ALK...

September 17, 2025 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

ALK and GenSci partner to expand the AIT market in China

ALK and GenSci partner to expand the AIT market in China Inside Information GenSci is granted exclusive rights to ALK’s house dust mite AIT products in China. ALK will be eligible for upfront and milestone payments of up to DKK 1.3 billion in addition to income from supplying GenSci with products.Partnership also aims to accelerate the introduction of a broader portfolio in China.Partnership is projected to become accretive to earnings margin in the medium term but is not expected to materially impact ALK’s revenue and earnings (EBIT) in 2025. ALK (ALKB:DC / OMX: ALK B) today announced a...

September 17, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch